Bio-Path Holdings, Inc. (BPTH)
OTCMKTS · Delayed Price · Currency is USD
0.1302
-0.0073 (-5.31%)
Aug 15, 2025, 2:19 PM EDT
Bio-Path Holdings Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
10
Market Cap
1.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 84.04M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.17M |
| BioStem Technologies | 332.45M |
Bio-Path Holdings News
- 2 months ago - Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25 - Newsfile Corp
- 2 months ago - Bio-Path Holdings Provides Clinical and Operational Update - GlobeNewsWire
- 3 months ago - Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025 - GlobeNewsWire
- 3 months ago - Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 5 months ago - Bio-Path GAAP EPS of -$4.12 - Seeking Alpha
- 5 months ago - Bio-Path Holdings Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - GlobeNewsWire
- 6 months ago - ARMISTICE CAPITAL, LLC Acquires Significant Stake in Bio-Path Holdings Inc - GuruFocus